 This open-label, multicenter, dose-escalation and expansion trial is designed to evaluate the safety and preliminary efficacy of inhaled DV281 in combination with an approved anti-PD-1 inhibitor for the treatment of NSCLC and to select a recommended phase 2 dose RP2D. 